**Name of Journal:** **World Journal of Clinical Cases**

**Manuscript NO: 41854**

**Manuscript Type: MINIREVIEWS**

**Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome**

Martinez-Cabriales SA *et al*. DReSS syndrome and the liver

**Sylvia A Martinez-Cabriales, Neil H Shear, Emmanuel I Gonzalez-Moreno**

**Sylvia A Martinez-Cabriales, Neil H Shear,** Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada

**Sylvia A Martinez-Cabriales,** Internal Medicine Department, Dermatology Division, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León 64460, Mexico

**Emmanuel I Gonzalez-Moreno,** Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta T2N 4Z6, Canada

**Emmanuel I Gonzalez-Moreno,** Internal Medicine Department, Gastroenterology Division, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León 64460, Mexico

**ORCID number:** Sylvia A Martinez-Cabriales (0000-0002-0190-5229); Neil H Shear (0000-0001-9151-1145); Emmanuel I Gonzalez-Moreno (0000-0002-0661-6928).

**Author contributions**: Martinez-Cabriales SA designed research, performed research, analyzed data, wrote the paper, and approved the final manuscript version; Shear NH analyzed data, wrote the paper, and approved the final manuscript version; Gonzalez-Moreno EI designed research, performed research, analyzed data, wrote the paper, and approved the final manuscript version.

**Conflict-of-interest statement:** The authors have no conflict of interest and no financial support to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author:** **Emmanuel I Gonzalez-Moreno**, **MD, Assistant Professor, Staff Physician,** Department of Medicine, Division of Gastroenterology, University of Calgary, Teaching, Research, and Wellness Building, 6D58, 3280 Hospital Drive NW, Calgary, Alberta T2N 4Z6, Canada. [emmanuel.gonzalezmor@ucalgary.ca](mailto:emmanuel.gonzalezmor@ucalgary.ca)

**Received:** September 5, 2018

**Peer-review started:** September 6, 2018

**First decision:** October 11, 2018

**Revised:** February 5, 2019

**Accepted:** February 26, 2019

**Article in press:**

**Published online:**

**Abstract**

First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.

**Key words:** Drug reaction, eosinophilia, and systemic symptoms syndrome; Severe cutaneous drug reactions; Drug-induced hypersensitivity syndrome; Drug-induced liver injury; Acute liver failure

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered a severe cutaneous drug reaction. It can present with a broad spectrum of clinical manifestations making its diagnosis challenging. Factors associated with a poor prognosis include delayed diagnosis, viral reactivation, the presence of systemic inflammatory response syndrome, and severe organ involvement. Liver injury, presented in more than half of DReSS patients, ranges from mild transaminasemia to acute liver failure and is one of the most common causes of death in these patients. Prompt withdrawal of the culprit agent and a multidisciplinary approach in patients with internal organ affection are of utmost importance.

Martinez-Cabriales SA, Shear NH, Gonzalez-Moreno EI. Liver involvement in the drug reaction, eosinophilia and systemic symptoms syndrome. *World J Clin Cases* 2019; in press

**INTRODUCTION**

Adverse drug reactions commonly involve the liver, the main organ in which drug metabolism occurs. It has been estimated that more than 600 medications have been related to significant liver injury[1]. Furthermore, herbal, complementary, and alternative medications, as well as illicit drugs such as anabolic steroids and amphetamines, have also been related to this problem[2,3]. Drug-induced liver injury (DILI) is one type of adverse drug reaction, which was ranked as one of the major causes of acute liver failure[4-6]. It is classified into two main types: intrinsic or idiosyncratic[7]. The former is all the predictable adverse drug reactions that are dose-dependent and manifested shortly after the drug was ingested[8]. In this case, the culprit is direct-chemical damage to the drug or its metabolite[9]. The idiosyncratic drug reaction, which is unpredictable, is characterized by a delayed onset of symptoms once the drug was taken[10]. It is subdivided into two categories: non-allergic and allergic reaction. In the non-allergic, the liver frequently is the only organ involved; however, in the allergic reaction, multisystemic organ involvement may be observed[11,12].

Drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS), also widely known as drug-induced hypersensitivity syndrome (DiHS), corresponds to a hypersensitivity drug reaction[13]. This syndrome was recognized in 1981 when Speilberg and Shear identified drug hepatotoxicity along with fever and a rash, which they called anticonvulsant hypersensitivity syndrome[14]. Several diagnostic criteria have been proposed for DReSS/DiHS, which is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis, and the liver is the most common organ involved[15]. Importantly, DReSS/DiHS might present with acute liver failure, which increases its mortality[16]. In this context, liver failure is usually classified in the group of drug-induced liver injuries[17]. This review focuses on the liver involvement present in DReSS/DiHS reported in the literature in case series.

**LITERATURE REVIEW**

We reviewed the literature and summarized all reported case-series of DReSS-associated with liver involvement obtained from MEDLINE and EMBASE between January 1990 and July 2018 using the following terms: “DReSS syndrome,” “drug reaction with eosinophilia and systemic symptoms,” “drug rash with eosinophilia and systemic symptoms,” “drug hypersensitivity and eosinophilia,” “drug-induced hypersensitivity syndrome”. The search was limited to the English language. After gathering all articles, we described the number of patients included, those with liver involvement, type of presentation, blood work, drug involved, other associations, treatment received, mortality, and follow-up.

**DEFINITIONS**

In this review, we will use the acronym DReSS/DiHS instead of DRESS as a recent review highlighted the importance of clarifying that eosinophilia is not mandatory to confirm this syndrome[18]. In 1996, Bocquet *et al*[19] established three criteria needed for diagnosis of DReSS/DiHS syndrome: skin eruption, eosinophilia (≥ 1.5 × 109/μL), and visceral involvement (transaminase elevation ≥ 2 times upper normal limit, lymphadenopathy > 2 cm in diameter, nephritis, interstitial pneumonia, or carditis). In 2006, Shiohara *et al*[20] proposed to include as diagnostic criteria the presence of human herpes virus 6 (HHV-6) reactivation, as they documented HHV-6 IgG titers and DNA 2-3 wk after the onset of the rash. The group suggested this virus to be a cause of this hypersensitivity syndrome. Finally, in 2007 the RegiSCAR group developed a new scoring system. Hospital admission as a result of the suspected drug-related reaction and at least three of the following findings: acute skin rash, fever, lymphadenopathy of at least two sites, the involvement of at least one internal organ, lymphocytosis/lymphocytopenia, peripheral eosinophilia, and thrombocytopenia. According to this scoring system, patients were classified into definite, probable, possible, or no diagnosis of DReSS/DiHS (Table 1)[21].

With regard of DILI, a previous definition set the following threshold for defining its diagnosis: elevation of AST and/or ALT or bilirubin or alkaline phosphatase > 2 upper limit of normal (ULN)[22,23]. Subsequently, given the adaptation or tolerance that may occur in up to 20% of drugs, the levels of transaminases elevations were modified to > 5 ULN without symptoms, or rise in alkaline phosphatase > 2 ULN, or rise in bilirubin > 2 ULN with any transaminases increasing. Alternatively, AST or ALT < 5 ULN with symptoms also defines DILI[24].

Patients with acute hepatitis and elevated prothrombin time or international normalized ratio levels without mental status changes are frequently labeled as having a severe acute liver injury[25].

**EPIDEMIOLOGY**

Although liver involvement is the most common visceral manifestation of patients with DReSS/DiHS, it presents mainly as hepatocellular injury, sometimes cholestasis, or both and rarely fulminant hepatitis and death[26]. Asymptomatic transaminasemia may occur in up to 20% of patients on drugs[27]. An estimation of a severe cutaneous drug reaction is about 1 of every 1000 hospitalized patients[28]. The DReSS/DiHS belongs to this category with an estimated incidence of one in 1000 to one in 10000 drug exposures[29,30] and mortality of approximately 5% to 10%[31]. Liver injury is the most common organ damage seen in cases of DReSS/DiHS with rates ranging from 51% to 87%[15,31-34]. Kardaun *et al*[35] reported that liver injury was the most common internal organ involvement seen in 75% (81/114) of DReSS/DiHS cases, in which 91% of the cases had visceral organ involvement. Shiohara[20] reported liver complications in up to 70% of drug-induced hypersensitivity syndrome patients. Cacoub *et al*[13] reported liver injury in 94% of DReSS/DiHS patients. One study reported β-lactams antibiotics, allopurinol, non-steroidal anti-inflammatory drugs, and sulfonamide as the most commonly associated drugs with DReSS/DiHS accompanied by liver dysfunction in 23 cases[36]. Another study reported sulfonamides (13/14; 92.9%), followed by antiepileptic drugs (19/22; 86.3%), and allopurinol (15/19; 78%) to have the highest risk of inducing liver injury in DReSS/DiHS [37]. To put DILI in context, Russo *et al*[38] reported that drug hepatotoxicity was the cause in 15% of liver transplantation as a result of acute liver failure from 2291 transplants in the United States between 1990 and 2002. Even though acetaminophen either as a single treatment or combined with another drug, was the principal drug related in 133/270 (49%) cases, idiosyncratic liver injury leading to 42% of liver transplants, was associated with four drugs: isoniazid, propylthiouracil, phenytoin, and valproate[38].

**PATHOGENESIS**

The pathogenesis of DReSS/DiHS is multifactorial including genetic polymorphisms and environmental factors. One hypothesis is based on the combination of a drug covalently joined to a protein acting as a hapten, accompanied by a co-stimulatory trigger-virus infection or reactivation, bacterial infection, or inflammatory disorder in a genetically susceptible individual leading to T-cell responses to the antigen, which could be expressed on the hepatocytes surface[39]. Studies have shown the presence of drug-specific cytotoxic T cells in the serum and liver of DILI patients and the skin of DReSS/DiHS patients[40,41]. These cells, which release perforin, granzyme B, and Fas⁄Fas L-dependent cell death, are believed to induce cell death in both organs[40,42].

Another proposed mechanism involves the immune response to reactivation of latent viruses of the herpesvirus family[43,44], which is seen in DReSS/DiHS complicated cases. It is hypothesized that DReSS/DiHS triggers reactivation of latent viral infection, which may produce a viral exanthema of fevers and rash that may overlap with, or be difficult to distinguish from DReSS/DiHS. Tohyama *et al*[43] compared 100 patients with or without an increase of anti-HHV-6 IgG titers and reported that the flare-up of symptoms such as fever and hepatitis was closely related to HHV-6 reactivation. In Eshki *et al*’s[45] retrospective study, only seven patients were examined for an active HHV-6 infection. An active HHV-6 infection was found in six patients, including a patient with fulminant liver failure. Further tests confirmed that HHV-6 infection was a reactivation and not a primary infection. Furthermore, HHV-6 may also cause hepatitis, including fulminant liver failure that is rapidly reversed when antiviral treatment is promptly initiated[46].

Liver damage in patients with DReSS/DiHS could be caused by eosinophilic infiltration driven by interleukin IL-5[47-49]. Hypereosinophilia, if persistent, can be toxic to endothelial cells and contribute to organ damage such as interstitial nephritis, pneumonitis, myositis, eosinophilic carditis, pancreatitis, thyroiditis or encephalitis, and possibly hepatitis[21].

**CLINICAL PRESENTATION**

The liver may be the first organ involved in a hypersensitivity drug reaction[37]. It could range from a mild increase of liver enzymes to acute fulminant hepatic failure with the cholestatic type as the most common. The cholestatic pattern is characterized by increased serum transaminases and alkaline phosphatase with prolonged jaundice after drug withdrawal. The hepatocellular pattern presents with increased serum transaminases, minimal serum alkaline phosphatase elevation, and variable jaundice. A mixed pattern has combined features of hepatocellular and cholestatic injury (Figure 1). Peyrière *et al*[15] reported liver involvement in more than 60% of 216 DReSS/DiHS cases with a hepatocellular necrosis more common than the cholestasis. Lin *et al*[37] reported that atypical lymphocytosis was seen more frequently on DReSS/DiHS cases with liver injury than cases without liver involvement (74.2% *vs* 30.0%, *P* = 0.010). One study reported that younger patients most commonly presented with a hepatocellular-type, and that the cholestatic-type was seen more often in older patients (*P* = 0.044).

Compared to other severe drug hypersensitivity reactions such as Stevens-Johnson syndrome, a study found a more severe hepatocellular pattern and a moderate to severe cholestatic-type liver injury along with longer liver recovery in DReSS/DiHS cases. They emphasized that the long duration of the liver involvement could last months after the rash resolved[36]. Wang *et al*[50] reported a hyperbilirubinemia in 12 (31.58%) patients, aspartate aminotransferase (AST) elevation (> 100 IU/L) in 19 (50.50%) patients, and 9 (23.68%) patients developed hepatic failure. Several case reports have reported liver injury before skin eruption. Lin *et al*[37] noticed this clinical presentation in 9.7% of cases. Lee *et al*[17] reported that renal dysfunction was more common in patients with liver dysfunction (39% *vs* 1%, *P* = 0.001), and patients with liver dysfunction were more likely to have renal dysfunction (96% *vs* 34%, *P* = 0.001). Lymphadenopathy was also commonly seen in patients with liver involvement (23% *vs* 6%, *P* = 0.005). Mortality was significantly higher in patients with liver dysfunction (11% *vs* 1%, *P* = 0.018). Ichai *et al*[16] described the histological features on the liver from DReSS/DiHS cases. They reported acute hepatitis with cytotoxic phenotype. Eosinophils were found in five of seven cases. Kupffer cell hyperplasia with erythrophagocytosis was observed in six of seven cases. They also reported a diminished factor V level at admission (less than 40%), or a reduction at day 2 was predictive of death or liver transplant (Table 2).

**SKIN BIOPSY**

Lin *et al*[37] did not find any difference in the eosinophils in the dermis between patients with or without liver injury (64.5% *vs* 60%, *P* = 1). On the other hand, they reported that eosinophils in the dermis were present more frequently in patients with non-severe hypersensitivity hepatitis (88.9% *vs* 30.8%, *P* = 0.002), concluding that the extreme group cases might be more related to the immunoallergic attack to the hepatocytes[37]. Walsh *et al*[51] reported that patients with clinical presentation of erythema multiforme-like were associated with higher elevations of AST (*P* = 0.01), concluding these patients have worse liver involvement[51].

**TREATMENT**

Although further studies are needed to evaluate the role of systemic corticosteroids in drug-induced systemic hypersensitivity and liver injury, it seems this therapy has a role in the treatment with DReSS/DiHS and liver involvement. A favorable outcome has been reported when fulminant hepatitis associated with DReSS/DiHS was treated with intensive corticosteroid therapy (methylprednisolone 1 g/d) for 3 d (3750 mg prednisone within 30 d)[52]. On the other hand, the study by Lee *et al*[36] demonstrated that in patients with DReSS/DiHS associated with liver injury, the use of systemic corticosteroids did not confer additional benefits regarding disease duration and recovery of liver function.

**MORTALITY**

Concerning DReSS/DiHS, acute-stage mortality ranges from 5% to 10% and is mainly attributed to specific liver injury, myocardial or pulmonary lesions, and hemophagocytosis[19,26]. Fifteen percent of liver transplantation cases in the United States are caused by DILI[38]. The mortality of 10% in those patients with a combination of hepatocellular injury and jaundice, first described by Zimmerman, has been confirmed in several studies[53-55]. In their case-series Ichai *et al*[16] reported that 43.7% of patients (7/16) with DReSS/DiHS related acute liver injury/acute liver failure underwent transplantation (*n* = 5) or died (*n* = 2).

**CONCLUSION**

Although rare, DReSS/DiHS is considered a severe cutaneous drug reaction, which could potentially lead to death, especially in patients with delayed diagnosis, viral reactivation, the presence of systemic inflammatory response syndrome, and severe organ involvement. A better understanding of its pathophysiology is required to elucidate risk factors for severe visceral involvement, as it is demonstrated to be the main cause of mortality. Patients with ongoing deterioration of liver function must be tested for reactivation of latent viruses of the herpesvirus family. Furthermore, a multidisciplinary approach in patients with severe internal organ affection is of utmost importance.

**REFERENCES**

1 **Navarro VJ**, Senior JR. Drug-related hepatotoxicity. *N Engl J Med* 2006; **354**: 731-739 [PMID: 16481640 DOI: 10.1056/NEJMra052270]

2 **Watkins PB**, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. *Hepatology* 2006; **43**: 618-631 [PMID: 16496329 DOI: 10.1002/hep.21095]

3 **Davern TJ**. Drug-induced liver disease. *Clin Liver Dis* 2012; **16**: 231-245 [PMID: 22541696 DOI: 10.1016/j.cld.2012.03.002]

4 **Døssing M**, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. *Drug Saf* 1993; **9**: 441-449 [PMID: 8129864]

5 **Ostapowicz G**, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002; **137**: 947-954 [PMID: 12484709 DOI: 10.7326/0003-4819-137-12-200212170-00007]

6 **Bakke OM**, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. *Clin Pharmacol Ther* 1995; **58**: 108-117 [PMID: 7628177 DOI: 10.1016/0009-9236(95)90078-0]

7 **Gunawan BK**, Kaplowitz N. Mechanisms of drug-induced liver disease. *Clin Liver Dis* 2007; **11**: 459-475, v [PMID: 17723915 DOI: 10.1016/j.cld.2007.06.001]

8 **Hamilton LA**, Collins-Yoder A, Collins RE. Drug-Induced Liver Injury. *AACN Adv Crit Care* 2016; **27**: 430-440 [PMID: 27959299 DOI: 10.4037/aacnacc2016953]

9 **Shehu AI**, Ma X, Venkataramanan R. Mechanisms of Drug-Induced Hepatotoxicity. *Clin Liver Dis* 2017; **21**: 35-54 [PMID: 27842774 DOI: 10.1016/j.cld.2016.08.002]

10 **Chalasani NP**, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol* 2014; **109**: 950-66; quiz 967 [PMID: 24935270 DOI: 10.1038/ajg.2014.131]

11 **Kaplowitz N**. Biochemical and cellular mechanisms of toxic liver injury. *Semin Liver Dis* 2002; **22**: 137-144 [PMID: 12016545 DOI: 10.1055/s-2002-30100]

12 **Kaplowitz N**. Idiosyncratic drug hepatotoxicity. *Nat Rev Drug Discov* 2005; **4**: 489-499 [PMID: 15931258 DOI: 10.1038/nrd1750]

13 **Cacoub P**, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. *Am J Med* 2011; **124**: 588-597 [PMID: 21592453 DOI: 10.1016/j.amjmed.2011.01.017]

14 **Shear NH**, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. *J Clin Invest* 1988; **82**: 1826-1832 [PMID: 3198757 DOI: 10.1172/jci113798]

15 **Peyrière H**, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys D; Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2006; **155**: 422-428 [PMID: 16882184 DOI: 10.1111/j.1365-2133.2006.07284.x]

16 **Ichai P**, Laurent-Bellue A, Saliba F, Moreau D, Besch C, Francoz C, Valeyrie-Allanore L, Bretagne SR, Boudon M, Antonini TM, Artru F, Pittau G, Roux O, Azoulay D, Levesque E, Durand F, Guettier C, Samuel D. Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors. *Transplantation* 2017; **101**: 1830-1837 [PMID: 28207633 DOI: 10.1097/TP.0000000000001655]

17 **Lee WM**, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop. *Hepatology* 2008; **47**: 1401-1415 [PMID: 18318440 DOI: 10.1002/hep.22177]

18 **Martínez-Cabriales SA**, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? *Am J Clin Dermatol* 2019; [PMID: 30652265 DOI: 10.1007/s40257-018-00416-4]

19 **Bocquet H**, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). *Semin Cutan Med Surg* 1996; **15**: 250-257 [PMID: 9069593 DOI: 10.1016/S1085-5629(96)80038-1]

20 **Shiohara T**, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. *Allergol Int* 2006; **55**: 1-8 [PMID: 17075280 DOI: 10.2332/allergolint.55.1]

21 **Kardaun SH**, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2007; **156**: 609-611 [PMID: 17300272 DOI: 10.1111/j.1365-2133.2006.07704.x]

22 **Bénichou C**. Criteria of drug-induced liver disorders. Report of an international consensus meeting. *J Hepatol* 1990; **11**: 272-276 [PMID: 2254635 DOI: 10.1016/0168-8278(90)90124-A]

23 **Danan G**, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* 1993; **46**: 1323-1330 [PMID: 8229110]

24 **Fontana RJ**, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. *Hepatology* 2010; **52**: 730-742 [PMID: 20564754 DOI: 10.1002/hep.23696]

25 **Hassan A**, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. *Liver Int* 2019; **39**: 31-41 [PMID: 30003672 DOI: 10.1111/liv.13931]

26 **Duong TA**, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. *Lancet* 2017; **390**: 1996-2011 [PMID: 28476287 DOI: 10.1016/S0140-6736(16)30378-6]

27 **Zimmerman HJ**. Drug-induced liver disease. *Drugs* 1978; **16**: 25-45 [PMID: 352664 DOI: 10.2165/00003495-197816010-00002]

28 **Roujeau JC**, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med* 1994; **331**: 1272-1285 [PMID: 7794310 DOI: 10.1056/nejm199411103311906]

29 **Fiszenson-Albala F**, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. *Br J Dermatol* 2003; **149**: 1018-1022 [PMID: 14632808 DOI: 10.1111/j.1365-2133.2003.05584.x]

30 **Li LF**, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. *Clin Exp Dermatol* 2006; **31**: 642-647 [PMID: 16901302 DOI: 10.1111/j.1365-2230.2006.02185.x]

31 **Chen YC**, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. *Arch Dermatol* 2010; **146**: 1373-1379 [PMID: 20713773 DOI: 10.1001/archdermatol.2010.198]

32 **Chiou CC**, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, Hu S, Hong HS, Chung WH. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. *J Eur Acad Dermatol Venereol* 2008; **22**: 1044-1049 [PMID: 18627428 DOI: 10.1111/j.1468-3083.2008.02585.x]

33 **Funck-Brentano E**, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O, Valeyrie-Allanore L. Therapeutic management of DRESS: a retrospective study of 38 cases. *J Am Acad Dermatol* 2015; **72**: 246-252 [PMID: 25592341 DOI: 10.1016/j.jaad.2014.10.032]

34 **Ben m'rad M**, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y, Guesmi M, Rollot F, Dehoux M, Guillevin L, Moachon L. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. *Medicine (Baltimore)* 2009; **88**: 131-140 [PMID: 19440116 DOI: 10.1097/MD.0b013e3181a4d1a1]

35 **Kardaun SH**, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *Br J Dermatol* 2013; **169**: 1071-1080 [PMID: 23855313 DOI: 10.1111/bjd.12501]

36 **Lee T**, Lee YS, Yoon SY, Kim S, Bae YJ, Kwon HS, Cho YS, Moon HB, Kim TB. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. *J Am Acad Dermatol* 2013; **69**: 407-415 [PMID: 23632341 DOI: 10.1016/j.jaad.2013.03.024]

37 **Lin IC**, Yang HC, Strong C, Yang CW, Cho YT, Chen KL, Chu CY. Liver injury in patients with DRESS: A clinical study of 72 cases. *J Am Acad Dermatol* 2015; **72**: 984-991 [PMID: 25801338 DOI: 10.1016/j.jaad.2015.02.1130]

38 **Russo MW**, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. *Liver Transpl* 2004; **10**: 1018-1023 [PMID: 15390328 DOI: 10.1002/lt.20204]

39 **Matzinger P**. Tolerance, danger, and the extended family. *Annu Rev Immunol* 1994; **12**: 991-1045 [PMID: 8011301 DOI: 10.1146/annurev.iy.12.040194.005015]

40 **Holt MP**, Ju C. Mechanisms of drug-induced liver injury. *AAPS J* 2006; **8**: E48-E54 [PMID: 16584133 DOI: 10.1208/aapsj080106]

41 **Pichler WJ**, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, Naisbitt D. Cellular and molecular pathophysiology of cutaneous drug reactions. *Am J Clin Dermatol* 2002; **3**: 229-238 [PMID: 12010068 DOI: 10.2165/00128071-200203040-00001]

42 **Posadas SJ**, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. *J Allergy Clin Immunol* 2002; **109**: 155-161 [PMID: 11799383]

43 **Tohyama M**, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, Urano Y, Matsumoto K, Iijima M, Shear NH. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. *Br J Dermatol* 2007; **157**: 934-940 [PMID: 17854362 DOI: 10.1111/j.1365-2133.2007.08167.x]

44 **Tohyama M**, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, Hashimoto K. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. *Arch Dermatol* 1998; **134**: 1113-1117 [PMID: 9762024 DOI: 10.1001/archderm.134.9.1113]

45 **Eshki M**, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. *Arch Dermatol* 2009; **145**: 67-72 [PMID: 19153346 DOI: 10.1001/archderm.145.1.67]

46 **Alexanian D**, Birg A, Volpicelli N, Glass J, McCarthy D. Latent Hepatitis Virus Reactivation Due to Drug Reaction: DRESSed to Kill? *Dig Dis Sci* 2018; **63**: 1143-1147 [PMID: 29594978 DOI: 10.1007/s10620-018-5028-1]

47 **Um SJ**, Lee SK, Kim YH, Kim KH, Son CH, Roh MS, Lee MK. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. *J Investig Allergol Clin Immunol* 2010; **20**: 556-562 [PMID: 21313995]

48 **Roujeau JC**. Clinical heterogeneity of drug hypersensitivity. *Toxicology* 2005; **209**: 123-129 [PMID: 15767024 DOI: 10.1016/j.tox.2004.12.022]

49 **Tas S**, Simonart T. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). *Acta Clin Belg* 1999; **54**: 197-200 [PMID: 10544509 DOI: 10.1053/j.ajkd.2009.07.013]

50 **Wang XQ**, Lv B, Wang HF, Zhang X, Yu SY, Huang XS, Zhang JT, Tian CL, Lang SY. Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients. *Clin Neurol Neurosurg* 2015; **138**: 1-7 [PMID: 26209753 DOI: 10.1016/j.clineuro.2015.07.008]

51 **Walsh S**, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, Creamer D. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. *Br J Dermatol* 2013; **168**: 391-401 [PMID: 23034060 DOI: 10.1111/bjd.12081]

52 **Descloux E**, Argaud L, Dumortier J, Scoazec JY, Boillot O, Robert D. Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation. *Intensive Care Med* 2005; **31**: 1727-1728 [PMID: 16283166 DOI: 10.1007/s00134-005-2846-3]

53 **Björnsson E**, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. *J Hepatol* 2009; **50**: 511-517 [PMID: 19155082 DOI: 10.1016/j.jhep.2008.10.021]

54 **Andrade RJ**, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 2005; **129**: 512-521 [PMID: 16083708 DOI: 10.1016/j.gastro.2005.05.006]

55 **Björnsson E**, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005; **42**: 481-489 [PMID: 16025496 DOI: 10.1002/hep.20800]

56 **Mansur AT**, Pekcan Yaşar S, Göktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. *Int J Dermatol* 2008; **47**: 1184-1189 [PMID: 18986457 DOI: 10.1111/j.1365-4632.2008.03827.x]

57 **Picard D**, Janela B, Descamps V, D'Incan M, Courville P, Jacquot S, Rogez S, Mardivirin L, Moins-Teisserenc H, Toubert A, Benichou J, Joly P, Musette P. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. *Sci Transl Med* 2010; **2**: 46ra62 [PMID: 20739682 DOI: 10.1126/scitranslmed.3001116]

58 **Ang CC**, Wang YS, Yoosuff EL, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. *J Am Acad Dermatol* 2010; **63**: 219-227 [PMID: 20605253 DOI: 10.1016/j.jaad.2009.08.050]

59 **Wongkitisophon P**, Chanprapaph K, Rattanakaemakorn P, Vachiramon V. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. *Acta Derm Venereol* 2012; **92**: 200-205 [PMID: 22002792 DOI: 10.2340/00015555-1222]

60 **Uhara H**, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. *J Eur Acad Dermatol Venereol* 2013; **27**: 722-726 [PMID: 22540194 DOI: 10.1111/j.1468-3083.2012.04547.x]

61 **Sultan SJ**, Sameem F, Ashraf M. Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients. *Int J Dermatol* 2015; **54**: 537-542 [PMID: 24738653 DOI: 10.1111/ijd.12331]

62 **Avancini J**, Maragno L, Santi CG, Criado PR. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. *Clin Exp Dermatol* 2015; **40**: 851-859 [PMID: 26271788 DOI: 10.1111/ced.12682]

63 **Lee JY**, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. *Int J Dermatol* 2017; **56**: 944-951 [PMID: 28718873 DOI: 10.1111/ijd.13667]

64 **Wang L**, Mei XL. Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective Analysis of 104 Cases over One Decade. *Chin Med J (Engl)* 2017; **130**: 943-949 [PMID: 28397724 DOI: 10.4103/0366-6999.204104]

65 **Wu X**, Yang F, Chen S, Xiong H, Zhu Q, Gao X, Xing Q, Luo X. Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. *Acta Derm Venereol* 2018; **98**: 401-405 [PMID: 29242946 DOI: 10.2340/00015555-2867]

**P-Reviewer:** Ahmed OM, Carter WG, Tanaka N, Lin J **S-Editor:** Dou Y **L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Canada

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): D

Grade E (Poor): 0

Muscle pain &/or weakness,  CPK-3/ CPK-MM, abnormal EMG.

Drug exposition

ALT >2 x UNL on ≥ 2 successive dates **or** cB >2 UNL on ≥2 sdates orAST, TB, ALP all > 2 UNL

Eosinophilia > 0.7 × 109/ L-1

≥3 of the following clinical manifestations

Skin involvement

Fever

Lymphadenopathies

≥ 2 or more places

Hematologic abnormalities

≥ 1 organ involvement2

Atypical lymphocytes

Histology suggestive of DRESS

Extension: face, trunk and limbs.

Morphology: maculopapular rash; facial edema.

Other organ

Heart

Pancreas

Liver

Kidney

Lung

Amylase and/or lipase ≥ 2\*UNL

Cough &/or dyspnoea +: interstitial involvement on imaging &/or abnormal BALP, or HP &/or abnormal BG

Creatinine >1.5 times UNL for the patient on ≥2 sdates, &/or proteinuria >1g/d, haematuria, creaCl,, GFR

Myocarditis+:  CPK >2\*UNL,  CPK-2/MB, Troponin T > 0.01 µg/L, abnormal CXR/ECHO/CT/MRI/ ECG: abnormal ST-T or cDefects, EM HP

Muscle

Potential cases of DReSS/DiHS1

✚✚

**Figure 1 Diagnostic algorithm of drug reaction, eosinophilia, and systemic symptoms syndrome / drug-induced hypersensitivity syndrome case series.** ALT: Alanine aminotransaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; BALP: Broncho-alveolar lavage fluid; BG: Blood gasses; cB: Conjugated bilirubin; cdefects: Conduction defects; CPK: Creatine phosphokinase; CPK-2/MB: Creatine phosphokinase for heart muscle involvement; CPK-3/CPK-MM: Creatine phosphokinase for skeletal muscle involvement; creaCl: Creatinine clearance; CT: Computed tomography; CXR: Chest-x-ray; ECG: Electrocardiogram; ECHO: Echocardiogram; EMG: Electromyography; EM: Endomyocardial; HP: Histopathology; MRI; TB: Total bilirubin; UNL: Upper normal limit.1The RegiSCAR criteria should be done to potential cases of DReSS for more accurate diagnosis and classification (see Table 1). 2Organ involvement after exclusion of other explanations.

**Table 1 RegiSCAR scoring system for classifying drug reaction, eosinophilia, and systemic symptoms syndrome/drug-induced hypersensitivity syndrome**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Clinical manifestations** | **SCORE** | | | | **Range** | |
| **-1** | **0** | **1** | **2** | **Min** | **Max** |
| Fever | No/U | Yes |  |  | -1 | 0 |
| Enlarged lymph nodes |  | No/U | Yes |  | 0 | 1 |
| Eosinophilia | | | | | | |
| Eosinophils |  | No/U | 700-1499/μL | ≥ 1500/μL | 0 | 2 |
| Eosinophils, if leukocytes < 4000 |  | No/U | (10%-19.9%) | (≥ 20%) | 0 | 2 |
| Atypical lymphocytes |  | No/U | Yes |  | 0 | 1 |
| Skin involvement | | | | | | |
| Skin rash extent, % BSA |  | No/U | > 50% |  | -2 | 2 |
| Skin rash suggesting DReSS | No | U | Yes |  |  |  |
| Biopsy suggesting DReSS | No | Yes/U |  |  |  |  |
| Organ involvement1 | | | | | | |
| Liver |  | No/U | Yes |  | 0 | 2 |
| Kidney |  | No/U | Yes |  | 0 | 2 |
| Lung |  | No/U | Yes |  | 0 | 2 |
| Muscle/heart |  | No/U | Yes |  | 0 | 2 |
| Pancreas |  | No/U | Yes |  | 0 | 2 |
| Other organ(s) |  | No/U | Yes |  | 0 | 2 |
| Resolution ≥ 15 d | No/U | Yes |  |  | -1 | 0 |
| Evaluation other potential causes: ANA; blood culture; serology for HVA/HVB/HVC/Chlamydia-/ Mycoplasma pneumonia; other serology/PCR. |  |  |  |  |  |  |
| If none positive and ≥ 3 of above negative |  |  | Yes |  | 0 | 1 |
| Total score | | | | | -4 | 9 |
| Final score meaning: < 2: no case; 2-3 possible case; 4-5: probable case; and > 5: definite case | | | | | | |

1After exclusion of other explanations: 1 = 1 organ, 2 = ≥ 2 organs. Adapted from Kardaun *et al*[21]. U: Unknown/unclassifiable; DReSS: Drug reaction, eosinophilia, and systemic symptoms syndrome; ANA: Antinuclear antibody; PCR: Polymerase chain reaction.

**Table 2 Liver involvement reported in drug reaction, eosinophilia, and systemic symptoms syndrome/drug-induced hypersensitivity syndrome case series**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| * **Author** | * **N** | * **Liver, *n* (%)** | * **Presentation, *n* (%)** | * **Blood work,** * ***n* (%)** | * **Drug, *n* (%)** | * **Associations** | * **Treatment** | * **Mortality,** * ***n* (%)** | * **Follow-up,** * ***n* (%)** |
| * Chiou *et al*[32] | * 30 (M: 15 F: 15) | * 26 (86.6) | * Jaundice 5 (16.6); Mild LI to FH; Toxic liver 6 (20) | * Eos (> 1500/ μL) 14 (48); Serology HHV-6: 7/11 (63); CMV, EBV, HSV IgM: all negative; HIV 3 | * Allopurinol 11 (37); CBZ 6 (20) | * RI 16 (53.3); ATL 13 (45) | HC/PDN: 22 (76); TS + Anti-H: 7 (23) | * 3 (10) (acute RF, sepsis, and GA bleeding) | * DM type 1: 2 patients |
| * Mansur *et al*[56]1 | * 31 (M: 15; F: 16) | * 22 (71) | * 2LI: > 2 fold of UNP to 20 –fold of increase; Hepatitis 16 (51); Hepatomegaly 7 (22.6) | * ALT: 2–5 fold increase 3 (10.0); ≥ 5 fold increase 4 (13.3); AST: 2–5 fold increase 1 (3.3); ≥ 5 fold increase 4 (13.3); GGT: 2–5 fold increase 6 (20.7); ≥ 5 fold increase 9 (31); Eos (> 350) 18/28 (64.3) | * CBZ 11 (48); Phenytoin 11(35.4); Lamotrigine 3 (9.6) | * RI 2 (6.45) | MTP: 27; TS + anti-H: 3 | * One TEN patient died of sepsis | 6 (19.4) developed a blister dermatitis: 3 SJS and 3 TEN. All the hepatitis recovered well |
| * Ben m’rad *et al*[34] | * 24 (M: 12; F: 12) | * 22 (91.6) | * Cholangitis or non-lithiasis cholecystitis | * ALT increased in 22 patients; ≥ 5N 13 (54); Eos (> 500 μ/L) 12 (50); Serology/PCR for HHV6, HHV8, CMV, and EBV were negative | * Allopurinol 4; SSE 3; SMX-TMP 3 | * RI 4 (17); Heart 5 (21); ATL 14 | * PDN: 11 (45) | * 0 | * No relapses occurred; Sequelae: myocarditis 1; Steroid dependent: 1 |
| * Eshki *et al*[45] | * 15 (M: 5; F: 10) | * 9 (60) | * HP of FH: massive hepatic necrosis + eosinophilic and lymphocytic inflammatory infiltrates | * DNA PCR HHV-6: serum 6/7 patients; liver 1/7; CNS: 1/7; HHV-6-IgM and IgG1 patient with FH (reactivation); HIV+ I patient | * Allopurinol 4; Minocycline 3; Antiepileptics 3 | * FH + HHV-6: 1: Hypertensive encephalitis (HHV-6 DNA CSF): 1 * RI: 6 | Non-AT: 5; SS: 10; + IVIG: 3; LT: 1 | * 3 (20); MOF + DIC: 1 | * 14 were admitted to the ICU where 3 died; 1 Flared twice when tapering of SS |
| * Picard *et al*[57] | * 40 (M: 19 * F: 21) | * 39 (99) |  | * Eos 32 (80); EBV react 16 (42); HHV-6 react 17 (45); HHV-7 react 12 (32) | * Anticonvulsants 12 (30); Antibiotics 11 (27) | * RF 10 (25); FH 2 (5) | * LT: 1 | * 3 (7.5); Endocarditis (1) septicemia (1) stroke (1, unrelated to DReSS) | * 17 (42) symptoms were still present at 180 d |
| * Chen *et al*[31] | * 60 (M: 26, F: 34) | * 48 (80) | * LI > 2 UNL | * Eos (> 700/μL) 31 (52) * EBV and CMV IgG + 9 patients; HHV-6-IgG + 1 patient, but negative PCR (only patient tested) | * Allopurinol (32); Phenytoin (18); Dapsone (17) | * RI 24 (40); RF 5 (8); HF 4; ATL (63) | * SS: 45 (75); + IVIG: 2; Non-AT: 6 | * 6 (10) (1 MOF; 3 septic shock; 1 cardiogenic shock; 1 shock) | * Hyperthyroidism |
| * Ang *et al*[58] | * 27 (M: 12 F: 15) | * 26 (96.3) |  | * Liver enzymes > 10 UNL: 13 (48); Eos 22 (%); Serology was not done | * Phenytoin 5; CBZ 4 | * RI 4 (15); RF 2 | SS: 25 (93); TS: 2 (7); LT: 0 | * 0 | * 8 (32) flared while SS tapering; 17 completed SS treatment (7 to 160 d, mean of 50); Sequelae: RI 3; AT 1, and myocarditis 1 |
| * Um *et al*[47] | * 38 (M: 18, F: 20) | * 38 (100) |  | * ALT (mean 383.39 IU/L, range 26-3633); AST (mean 382.73 IU/L, range 28-2360); Eos (> 500/μL) 35 (91); Serology negative to CMV, EBV, or HSV | * Anticonvulsants 18 (47); Antibiotics 7 (18); NSAIDs 5 (13) | * RI 6 (16); ATL 18 (47) | TS + anti-H: 22 (58); SS: 16 (42) | * 1 (3) LF + opportunistic infection | * 36 (95) recovered completely; 1 (2.6) LI was lost at FU |
| * Wongkitisophon *et al*[59] | * 27 (M: 14; F: 13) | * 26 (96.3) | * LI > 2 UNL; Hepatomegaly (7.4) | * ALT mean 188 IU/L (*r* 132–1708); AST 132 IU/L (*r* 89–857); TB 9 (33.3) mean 32.7 μmol/L (*r* 18.9–244.2 μmol/L); Eos (> 700/μL) 19 (70) | * Phenytoin 9 (33) Allopurinol 4 (15) Nevirapine 4 (15) | * RI 2 (7); ATL (19) | Non-AT: 4; SS (DMT/PDNL): 23 (85.2) | * 1 (4) died from MOF | * 5 (19) relapse of DReSS during tapering of SS; 21 (77.8) recovered well; Sequelae: 5 (19) that recovered within 6 mo |
| * Kardaun *et al*[35] | * 117 (M: 52; F 65) | * 86/114 (75) | * Transiently disturbed; liver function tests; Hepatomegaly and coagulopathy | * Eos (≥ 1500 μL-1) 92 (81); (700–1499 μL-1) 16 (14); HIV 1; HHV-6 react 21/58 (36) | * Anticonvulsants 41 (35); Allopurinol 21 (18); Sulfonamide 14 (12) | * RI 40/108 (37); ATL 68/102 (67); SJS, TEN or AGEP features were seen in 8 patients | * NA | * 2 (2) | 1 overlap with SJS/TEN; and 1 overlap with AGEP |
| * Walsh *et al*[51] | * 27 (M: 10; * F: 17) | * 27 (100); TRC of HPB | * LI before rash 4 (14.8); Significant LI: 20; Mild LI: 7; Cholestatic pattern was associated with interface dermatitis (*P* = 0.036) | * AST mean 970 IU/L, median 250 (31-5183); GGT mean 522 IU/L, median 379 (9-1903); ALP mean 295 IU/L, median 266 (57-819); Eos (> 0.4 × 109/ L) 25 (93) | * Anticonvulsants 12; Antimicrobials 10; Anti-rheumatics 5 | * RI 2 (7); Pericarditis (1 patient); GA (1 patient) * MOD 3 patients | * LT: 2 | * 3 (11) All had severe liver injured. Two after failed LT | 18 patients completed FU and normalized liver function |
| * Lee *et al*[36] | * 23 (M: 12; F: 11) | * 23 (100) | * Significant LI 23 (100) | * ALT 186 IU/L (114.0-458.0); AST 207 IU/L (90.0-766.0); ALP 147 IU/L (116.0-338.0); TB 1.1 (0.8-13.3); Eos 17 (74) | * Beta-lactams 7 (54); Allopurinol 3 (13); Sulfonamide 2 (15) | * RI 13 (56); If LI higher risk of RI (*P* < 0.001); and of LN (*P* = 0.005) | LT: (2 patients; 1 died); IVIG: 1 (4); PDNL | * 4 (17.39) | * Duration of the disease in survivors on steroids: 25.3 ± 14.8 d |
| * Uhara *et al*[60] | * 12 (M: 4; F: 8) | * 11 (92) | * Peak of LI appeared 7 d after the rash (range 3-22); ALT mean 176 (range 91- 311) | * Eos (>1.5 × 109 ⁄ L) 4; HHV-6-IgG 12 (100) | * CBZ 6; Salazosulfapyridine 4 | * ATL 8 (66) | Non-AT on the first weeks of examination  Hydration: 7; TS: 5  PDN: 1 patient had RA; DMT (single dose): 1 | * 0 | * All patients recovered; 7 to 37 d (median, 18) after withdrawal of the drug |
| * Sultan *et al*[61] | * 17 (M: 8 F: 9) | * 17 (100) | * LI defined as ALT > 100 IU/L; Hyperbilirubinemia 11 (64.7); Hepatomegaly 5 (29.4) | * ALT (> 100 IU/L) 17 (100); AST (> 100 IU/L) 7 (41); HF 1 (5.9); Eos (> 1.5 9 109 cells/ ) 15 (88.2) | * Anti-convulsivants (65); Phenytoin 6 (35.3); Phenobarbitone 2 (12) | * RI 11 (64.7); RF 1 (5.9) requiring dialysis; ATL 2 (11.7) | * SS (DMT switched to PDNL): 17 (100) | * 1 (6) died of HF | * 13 (76.5) recovered without complication * 1 (5.9) DReSS recurrence after withdrawal of steroids |
| * Avancini *et al*[62] | * 27 (M: 17; F: 10) | * 23 (85.1) | * LI defined as liver enzyme level > 3 UNL | * ALT 569 ± 911.5 U/L (mean ± SD; 46–4347 U/L); AST 474 ± 743 U/L (mean ± SD; 38–2662 U/L); Eos 26 (96); HCV + 1 patient | * Phenytoin 12 (44); CBZ 8 (30) | * ATL 17 (62.9); Associated to and higher ALT (*r* = 0.62; *P* < 0.001) | * PDN: 27 (100); LT: (1 patient) | * 1 (4) due to HF | 1 AT |
| * Funck-Brentano *et al*[33] | * 38 (M: 19; F: 19) | * 29 (76) | * Cytolysis 27 (71). Duration of 47 d (12-120); Cholestasis 26 (68); No HF was observed | * Eos (> 7-1.5) 8 (21); (>1.5 × 109/L) 26 (68); PCR HHV-6 11/28 (39); EBV 3/28 (11); CMV 2/29 (7) | * Allopurinol 13 (34); CBZ 4 (11); Sulfonamide 4 (11) | * RI 21 (55); ORF 16 (42); FRF 8 (21); ATL 21 (55) | SS (MTP/PDN): 13 (34); TS: 25 (66) | * 1 (3); Hypovolemic shock few weeks post-discharged | * Treatment duration 40 d (15-360); Relapses 15 (39) |
| * Lin *et al*[37] | * 72 (M: 34; F: 38) | * 62 (86.1) | * LI before rash 6 (9.7); Pattern: * Cholestasis 23 (37.1); Mixed 17 (27.) * Hepatocellular 12 (19.4); Unknown 10 (16.1) | * Eos (> 700/ml) 49 (58.3); ALT values as high as 3806 U/L or ALP values of up to 2616 U/L | Anticonvulsants (30.6); Phenytoin 13 (18); Allopurinol; 19 (26.4)3; Sulfonamides 14 (19.4) | * ATL (79.2): related to LI (*P* = 0.010) * and with fever (*P* = 0.026). | * PDNL + IVIG: 1; NAC: 0 | * 0 | * 22 (35.5) recovered in 30 d; 40 (64.5) recovered after |
| * Lee *et al*[63] | * 25 (M: 11; F: 14) | * 20 (80) | * LI if liver enzymes > 2 UNL | * BT increased 6 (24); Eos (> 0.7 × 109/L), 20 (80), 7 of them had (> 1.5 9 109/L). PCR HHV-6 tested in 1 patient: negative | * CBZ (28); Allopurinol (16); Anti-tuberculosis drugs (12) | * RI 7 (28); ATL 12 (48); Pulmonary involvement 5 (20) | SS (MTP or PDN): 13 (52); + IVIG: 2 (8); TS + anti-H: 12 (48) | * 3 (12); 1 Septic shock + LI; 1 septic shock + LI +RF; 1 septic shock + LI+ RI + Pneumonia | * The remaining patients had fully recovered. No significant cutaneous sequelae |
| * Wang *et al*[64] | * 104 (M: 38; F: 66) | * 94 (90.4) | * Jaundice 5 patients | * Eos 72 (69.2): (0.7 × 109/L-1.499 × 109/L) 37 (35.6); (≥ 1.5 × 109/L) 35 (33.7); HIV 1 (1); Serology for HVA/HBV/HCV 18 (17.3) | * Antibiotics 37 (35.6); CBZ 7 (6.7); TCMs 14 (13.5) | * RI 9 (8.7) * ATL 26 (25); MOD 19 patients | * PDN: 58 (58) * + IVIG: 1 patient; + Cy: 1 patient; Anti-H: 45 (43); IVIG: 1 patient | * 1 (< 1) had progression of his previously renal disease + *Acinetobacter baumannii* | * 103 were successfully discharged |
| * Ichai *et al*[16] | * 16 (M: 5 F: 11) | (100) TTC | * ENC: 7 (43.75) Admission 3 (Grade I: 1; III: 2); After admission 4 * Liver necrosis (10%-90% of parenchymal surface) 7: panlobular 1; central; 3; periportal 1; spotty 2. Kupffer cell hyperplasia: 6; and Erythrophagocytosis | * ALT 1693 IU/L (1252-2256); PCR HHV6 5/6 (83); HIV+ 4 (25) | * Allopurinol 2; CBZ 2 * Anti-tuberculosis drugs 3 | * RI 5 (31.2) | NAC: 16 (100); PDNL: 9 (56); LT: 5 (31.2) | * 4 (25): 2 MOF; 1 LR 4 yr after LT; 1 systemic fungal infection + HF 4 d after LT | LT survival: 60%; DReSS recurrence 75 ± 91 d after LT in 3/5 patients. LR was rule out. DReSS recurrence in 1 patient 2 months after spontaneously recovery |
| * Wu *et al*[65] | * 52 (M: 34; F: 18) | 43 (83) | * LI if ALT >2 UNL | * Eos (> 700/μL) 42 (81); DNA HHV-6 17 (33); DNA EBV 10 (19) | * Allopurinol 18 (35); SSP 11 (21); CBZ 5 (10) | * RI 2 (4) | MTP: 52 (100); + IVIG: 32 (62) | * 3 (6) MOF + sepsis within 3 months post-discharge. | * 3 (6) AT |

1Case series with Anticonvulsant hypersensitivity syndrome. 2Authors reported that DReSS induced by phenytoin appeared sooner after the drug intake compared to carbamazepine (*P* = 0.01). 3Allopurinol was related to cholestatic pattern. Hepatocellular-type pattern was seen in younger people while the cholestatic-type was seen in elderly (*P* = 0.044). Patients treated with SS had more ATL and Eos than those treated with TS (*P* < 0.05), but no differences in liver involvement. AGEP: Acute generalized exanthematous pustulosis; Anti-H: Antihistamines; AHA: Autoimmune hemolytic anemia; AT: Autoimmune thyroid; ATL: Atypical lymphocytosis; BT: Bilirubin total; CBZ: Carbamazepine; CMV: Cytomegalovirus; CNS: Central nervous system; CSF: Cerebrospinal fluid; Cy: Cyclosporine; DIC: Disseminated intravascular coagulation; GA: Gastrointestinal; ICU: Intensive care unit; DMT: Dexamethasone; EBV: Epstein Barr virus; Eos: Eosinophilia; ENC: Encephalopathy; FH: Fulminant hepatitis; FU: Follow-up; HC: Hydrocortisone; HSV: Herpes simplex virus; HHV-6: Herpes virus type 6; HPB: Hepatobiliary disease; LN: Lymphadenopathies; LT: Liver transplant; LR: Liver rejection; MOD: Multi-organ damage; MOF: Multi-organ failure; MTP: Methylprednisolone; NA: Not-available; NAC: N-acetylcysteine; Non-AT: Non-active treatment; NSAIDs: Non-steroidal anti-inflammatory drugs; PCR: Polymerase chain reaction; PDN: Prednisone; PDNL: Prednisolone; RI: Renal injury; RF: Renal failure (ORF: Organic RF; FRF: Functional RF); SJS: Stevens–Johnson syndrome; SMX-TMP: Sulfamethoxazole-trimethoprim; SS: Systemic steroids; SSE: Sulfasalazine; SSP: Salazosulphapyridine; TEN: Toxic epidermal necrolysis; TMCs: Traditional Chinese Medicines; TRC: Tertiary Referral Center; TS: Topical steroids; TTC: Tertiary Transplant Center.